# OnCo record tnbc-early (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/tnbc-early/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "tnbc-early" ;
  schema:name "Early triple-negative breast cancer"@en ;
  schema:alternateName "Stage I to III triple-negative breast cancer"@en, "Operable triple-negative breast cancer"@en, "Curable TNBC"@en ;
  schema:description "Early triple-negative breast cancer is treated to cure. For tumours over 2 cm or with node involvement, chemotherapy plus the immunotherapy pembrolizumab before and after surgery has raised cure rates; BRCA carriers with cancer left at surgery add a year of olaparib, and others with residual cancer are offered capecitabine. Whether the tumour has vanished by surgery guides what comes next."@en ;
  schema:url <https://onco.cc/cancers/tnbc-early/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Triple-negative_breast_cancer> ;
  schema:citation <https://doi.org/10.1056/NEJMoa1910549>, <https://doi.org/10.1056/NEJMoa2409932>, <https://doi.org/10.1056/NEJMoa2105215>, <https://doi.org/10.1056/NEJMoa1612645> ;
  onco:tag "subtype-page" ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-trial-diversity/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-olympia-nejm-2021/> ;
  onco:pipeline <https://onco.cc/trials/ascent-05/>, <https://onco.cc/trials/optimice-pcr/>, <https://onco.cc/trials/scarlet-s2212/>, <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/drugs/sacituzumab-govitecan/>, <https://onco.cc/technologies/neoantigen-mrna-vaccine/>, <https://onco.cc/terms/tils/> ;
  onco:standardOfCare <https://onco.cc/terms/lumpectomy/>, <https://onco.cc/technologies/sentinel-node/>, <https://onco.cc/technologies/hypofractionated-radiotherapy/>, <https://onco.cc/terms/tils/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/epirubicin/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/trials/keynote-522/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/terms/pcr/>, <https://onco.cc/trials/optimice-pcr/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/trials/olympia/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/terms/rcb/>, <https://onco.cc/trials/ascent-05/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/terms/lumpectomy/>, <https://onco.cc/terms/mastectomy/>, <https://onco.cc/technologies/sentinel-node/>, <https://onco.cc/technologies/imrt-igrt/> .